Article

Mobile website educates parents on eye therapies

A new mobile website, DROPS101 Web Tools (Alcon), offers digital access to product information for moxifloxacin related to the treatment of bacterial conjunctivitis in children.

Fort Worth, TX-A new mobile website, DROPS101 Web Tools, takes the interaction between patients and health-care providers into the digital age by providing a one-stop, educational resource about commonly prescribed pediatric eye and ear treatments. Alcon is launching the site in response to growing demand for digital access to patient-centered materials.

The site offers digital access to product information related to the treatment of two extremely common child ailments: moxifloxacin HCI ophthalmic solution 0.5% (Moxeza) for the treatment of bacterial conjunctivitis caused by susceptible strains and ciprofloxacin 0.3% and dexamethasone 0.1% (Ciprodex Otic) for the treatment of acute otitis externa.

“We heard from doctors that patients need a one-click resource for prescribed eye and ear treatments. [The site] is another way we are expanding our commitment to meet the ever-evolving needs of health-care professionals and their patients,” said Amy Patyk, multi-channel marketing manager, Alcon U.S. “By offering mobile access to educational tools, health-care professionals can help their patients learn more about medication options and treatment support with the convenience of wireless technology.”

DROPS101 Web Tools are available in the United States only. For more information, medical providers or healthcare professionals can contact their Alcon sales representative or visit www.drops101.com.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.